## Biologically modified LDL increases the adhesive prope

Atherosclerosis 90, 119-126 DOI: 10.1016/0021-9150(91)90106-d

Citation Report

#	Article	IF	CITATIONS
1	The process of atherogenesis ? cellular and molecular interaction: from experimental animal models to humans. Diabetologia, 1992, 35, S34-S40.	2.9	80
2	Antioxidants: A biological defense mechanism for the prevention of atherosclerosis. Medicinal Research Reviews, 1993, 13, 161-182.	5.0	45
3	Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. Kidney International, 1993, 43, 1243-1250.	2.6	72
4	Pathogenesis and Treatment Perspectives of Chronic Graft Rejection (CVR). Immunological Reviews, 1993, 134, 83-98.	2.8	73
5	Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit. Atherosclerosis, 1993, 100, 171-181.	0.4	44
6	Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis, 1993, 103, 213-219.	0.4	58
7	Oxidized low-density lipoprotein enhances monocyte-endothelial cell binding against shear-stress-induced detachment. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1178, 221-227.	1.9	61
8	The Early Atherosclerotic Lesion — Morphology and Mechanisms. Vascular Medicine Review, 1993, vmr-4, 59-75.	0.2	2
9	Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 427-433.	3.8	99
10	Influence of nutrients and cytokines on endothelial cell metabolism Journal of the American College of Nutrition, 1994, 13, 224-231.	1.1	29
11	Nutrition, endothelial cell metabolism, and atherosclerosis. Critical Reviews in Food Science and Nutrition, 1994, 34, 253-282.	5.4	30
12	Spatial and temporal relationships between cadherins and PECAM-1 in cell-cell junctions of human endothelial cells Journal of Cell Biology, 1994, 126, 247-258.	2.3	183
13	The distribution of adhesion molecules in chronic periaortitis. Histopathology, 1994, 24, 23-32.	1.6	37
14	Evidence That Clucose Increases Monocyte Binding to Human Aortic Endothelial Cells. Diabetes, 1994, 43, 1103-1107.	0.3	144
15	Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Progress in Cardiovascular Diseases, 1995, 38, 129-154.	1.6	174
16	Oxidized LDL Induces Enhanced Antibody Formation and MHC Class II–Dependent IFN-γ Production in Lymphocytes From Healthy Individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1577-1583.	1.1	59
17	Vascular Mechanisms in the Development of Chronic Rejection1. Mikrozirkulation in Forschung Und Klinik, 1995, 21, 92-99.	0.1	2
18	Probucol, but not MaxEPA fish oil, inhibits mononuclear cell adhesion to the aortic intima in the rat model of atherosclerosis. Biochemistry and Cell Biology, 1995, 73, 283-288.	0.9	8

#	Article	IF	CITATIONS
19	Thyronines and probucol inhibition of human capillary endothelial cell-induced low density lipoprotein oxidation. Biochemical Pharmacology, 1995, 50, 1627-1633.	2.0	20
20	Modified low density lipoprotein and cytokines mediate monocyte adhesion to smooth muscle cells. Atherosclerosis, 1996, 127, 167-176.	0.4	48
21	Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis, 1996, 121, 93-103.	0.4	91
22	The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis, 1996, 125, 217-229.	0.4	26
23	Die Rolle des Endothels bei der Entstehung der Arteriosklerose. , 0, , .		0
24	Human Monocytes/Macrophages Release TNF-α in Response to Ox-LDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1573-1579.	1.1	192
25	Glucose-induced transmigration of monocytes is linked to phosphorylation of PECAM-1 in cultured endothelial cells. American Journal of Physiology - Endocrinology and Metabolism, 1996, 271, E711-E717.	1.8	26
26	Vitamins C and E and LDL Oxidation. Vitamins and Hormones, 1996, 52, 1-34.	0.7	19
27	Effect of vitamin e on human aortic endothelial cell responses to oxidative injury. Free Radical Biology and Medicine, 1996, 21, 505-511.	1.3	35
28	Antiatherogenic properties of zinc: Implications in endothelial cell metabolism. Nutrition, 1996, 12, 711-717.	1.1	112
29	Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. International Journal of Immunopharmacology, 1996, 18, 669-675.	1.1	145
30	Mechanism of Uptake of Copper-oxidized Low Density Lipoprotein in Macrophages Is Dependent on Its Extent of Oxidation. Journal of Biological Chemistry, 1996, 271, 11798-11805.	1.6	81
31	Chylomicrons induce E-Selectin and VCAM-1 Expression in endothelial cells. Experimental and Clinical Endocrinology and Diabetes, 1997, 105, 35-37.	0.6	23
32	High Affinity Saturable Uptake of Oxidized Low Density Lipoprotein by Macrophages from Mice Lacking the Scavenger Receptor Class A Type I/II. Journal of Biological Chemistry, 1997, 272, 12938-12944.	1.6	115
33	Inhibition of Low-Density Lipoprotein Oxidation by Oral Herbal Mixtures Maharishi Amrit Kalash-4 and Maharishi Amrit Kalash-5 in Hyperlipidemic Patients. American Journal of the Medical Sciences, 1997, 314, 303-310.	0.4	7
34	Zinc attenuates tumor necrosis factor-mediated activation of transcription factors in endothelial cells Journal of the American College of Nutrition, 1997, 16, 411-417.	1.1	72
35	Dietary antioxidants and cardioprotection—fact or fallacy?. Canadian Journal of Physiology and Pharmacology, 1997, 75, 228-233.	0.7	2
36	Native and Î <sup>3</sup> radiolysis-oxidized lipoprotein(a) increase the adhesiveness of rabbit aortic endothelium. Atherosclerosis, 1997, 132, 29-35.	0.4	14

#	Article	IF	CITATIONS
37	Endothelial Function. Drugs, 1997, 53, 1-10.	4.9	88
38	Antioxidants and Atherosclerotic Heart Disease. New England Journal of Medicine, 1997, 337, 408-416.	13.9	1,224
39	Association of Serum Antibodies to Heat-Shock Protein 65 With Borderline Hypertension. Hypertension, 1997, 29, 40-44.	1.3	64
40	DNA Fragmentation and Ultrastructural Changes of Degenerating Cells in Atherosclerotic Lesions and Smooth Muscle Cells Exposed to Oxidized LDL in Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2225-2231.	1.1	60
41	Cellular effects of hypercholesterolemia in modulation of cancer growth and metastasis: a review of the evidence. Surgical Oncology, 1997, 6, 179-185.	0.8	18
42	Antioxidants Inhibit the Expression of Intercellular Cell Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Induced by Oxidized LDL on Human Umbilical Vein Endothelial Cells. Free Radical Biology and Medicine, 1997, 22, 117-127.	1.3	215
43	Oxidizability of low-density lipoproteins from neoral and tacrolimus-treated renal transplant patients. Transplantation Proceedings, 1998, 30, 2043-2046.	0.3	27
44	Postischemic reperfusion injury and allograft arteriosclerosis. Transplantation Proceedings, 1998, 30, 4278-4280.	0.3	40
45	Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. Journal of the American College of Cardiology, 1998, 32, 711-716.	1.2	108
46	An Animal Model to Study Local Oxidation of LDL and Its Biological Effects in the Arterial Wall. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 884-893.	1.1	79
47	Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands. Atherosclerosis, 1998, 136, 297-303.	0.4	86
50	Cellular and molecular mechanisms in transplant arteriosclerosis (Review) International Journal of Molecular Medicine, 1998, 1, 279-88.	1.8	3
51	Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. American Journal of Clinical Nutrition, 1998, 68, 1208-1214.	2.2	161
52	Lipids and the endothelium. Cardiovascular Research, 1999, 43, 308-322.	1.8	108
53	Effects of Oxidized Low Density Lipoprotein, Lipid Mediators and Statins on Vascular Cell Interactions. Clinical Chemistry and Laboratory Medicine, 1999, 37, 243-51.	1.4	45
54	Autoantibodies to OxLDL Are Decreased in Individuals With Borderline Hypertension. Hypertension, 1999, 33, 53-59.	1.3	113
55	Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and β2-glycoprotein I (β2-GPI) in systemic lupus erythematosus. Clinical and Experimental Immunology, 1999, 115, 561-566.	1.1	40
56	Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clinical and Experimental Immunology, 1999, 116, 326-331.	1.1	160

#	Article	IF	CITATIONS
57	On the Role of Vitamin C and Other Antioxidants in Atherogenesis and Vascular Dysfunction. Proceedings of the Society for Experimental Biology and Medicine, 1999, 222, 196-204.	2.0	130
58	ANTIOXIDANT VITAMINS AND PREVENTION OF CARDIOVASCULAR DISEASE: LABORATORY, EPIDEMIOLOGICAL AND CLINICAL TRIAL DATA. Pharmacological Research, 1999, 40, 227-238.	3.1	115
59	Are there markers to initiate treatment of chronic rejection?. Transplantation Proceedings, 1999, 31, 1796-1798.	0.3	4
60	The effects of lipids on graft outcome. Transplantation Proceedings, 1999, 31, 14-15.	0.3	26
61	Heart allograft vascular disease. Atherosclerosis, 1999, 142, 243-263.	0.4	43
62	Vitamin E protects against polymorphonuclear leukocyte-dependent adhesion to endothelial cells. Journal of Leukocyte Biology, 1999, 65, 757-763.	1.5	64
63	Alphaâ€tocopherol protects against monocyte Macâ€1 (CD11b/CD18) expression and Macâ€1â€dependent adhesion to endothelial cells induced by oxidized lowâ€density lipoprotein. BioFactors, 2000, 11, 221-233.	2.6	17
64	The paradoxical relationship of aerobic exercise and the oxidative theory of atherosclerosis. , 2000, , 1053-1067.		3
65	Soy Protein Isolate Reduces the Oxidizability of LDL and the Generation of Oxidized LDL Autoantibodies in Rabbits with Diet-Induced Atherosclerosis. Journal of Nutrition, 2000, 130, 2641-2647.	1.3	28
66	Vitamin E and Leukocyte–Endothelial Cell Interactions. Antioxidants and Redox Signaling, 2000, 2, 821-825.	2.5	20
67	Induction of early atherosclerosis in CBA/J mice by combination of Trypanosoma cruzi infection and a high cholesterol diet. Atherosclerosis, 2000, 153, 273-282.	0.4	25
68	Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. Journal of the American College of Cardiology, 2000, 35, 277-283.	1.2	111
69	Oxidized LDL-Mediated Monocyte Adhesion to Endothelial Cells Does Not Involve NFκB. Biochemical and Biophysical Research Communications, 2001, 284, 239-244.	1.0	35
70	Immune Mechanisms in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1876-1890.	1.1	730
71	Pathophysiology of the progression of renal graft dysfunction. Transplantation Proceedings, 2001, 33, 299-301.	0.3	0
72	Antioxidant vitamins and prevention of cardiovascular disease: Epidemiological and clinical trial data. Lipids, 2001, 36, S53-S63.	0.7	149
73	Antibodies to Lysophosphatidylcholine Are Decreased in Borderline Hypertension. Hypertension, 2001, 37, 154-159.	1.3	10
74	Antioxidants and atherosclerosis. European Heart Journal Supplements, 2002, 4, B17-B21.	0.0	13

	Сітаті	on Report	
#	Article	IF	CITATIONS
75	Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmunity Reviews, 2002, 1, 233-237.	2.5	82
76	Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clinical Endocrinology, 2002, 56, 449-455.	1.2	23
77	Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. British Journal of Pharmacology, 2002, 135, 1175-1182.	2.7	88
78	The protective effects of monophosphoryl lipid A on the ischemic myocardium and endothelium in rats. Cardiovascular Drugs and Therapy, 2003, 17, 311-318.	1.3	2
79	Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 600-606.	1.4	36
80	Relationship between protective effect of xanthone on endothelial cells and endogenous nitric oxide synthase inhibitors. Bioorganic and Medicinal Chemistry, 2003, 11, 5171-5177.	1.4	29
81	Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactions. Atherosclerosis, 2003, 168, 239-244.	0.4	26
82	Increased microvascular permeability in the hamster cheek pouch induced by oxidized low density lipoprotein (oxLDL) and some fragmented apolipoprotein B proteins. Inflammation Research, 2003, 52, 215-220.	1.6	23
83	Circulating oxidized low-density lipoprotein is increased in hypertension. Clinical Science, 2003, 105, 615-620.	1.8	59
84	Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovascular Research, 2004, 61, 671-682.	1.8	198
85	The Autoantibody Repertoire Against Copper- or Macrophage-Modified LDL Differs in Normolipidemics and Hypercholesterolemic Patients. Journal of Clinical Immunology, 2004, 24, 170-176.	2.0	34
86	Characterization of native and oxidized human low-density lipoproteins by the Z-scan technique. Chemistry and Physics of Lipids, 2004, 132, 185-195.	1.5	36
87	Antioxidants and Prevention of Chronic Disease. Critical Reviews in Food Science and Nutrition, 2004, 44, 275-295.	5.4	875
88	Chemokines, Chemokine Receptors and Atherosclerosis. Current Topics in Membranes, 2005, , 223-253.	0.5	3
89	Systemic Lupus Erythematosus, Atherosclerosis, and Autoantibodies. Annals of the New York Academy of Sciences, 2005, 1051, 351-361.	1.8	46
90	Hemodialysis Procedure Does Not Affect the Levels of sICAM-1 and sVCAM-1 in Patients with End Stage Renal Disease. Renal Failure, 2005, 27, 315-321.	0.8	11
91	Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis, 2006, 188, 160-166.	0.4	157
92	Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia. Pharmacological Research, 2006, 54, 203-207.	3.1	23

#	Article	IF	CITATIONS
93	Carbamylated Low-Density Lipoprotein Induces Monocyte Adhesion to Endothelial Cells Through Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 826-832.	1.1	80
95	Common variants of apolipoprotein A-IV differ in their ability to inhibit low density lipoprotein oxidation. Atherosclerosis, 2007, 192, 266-274.	0.4	47
96	Role of PPAR-gamma in the Modulation of CD36 and FcgammaRII induced by LDL with Low and High Degrees of Oxidation During the Differentiation of the Monocytic THP-1 Cell Line. Cellular Physiology and Biochemistry, 2008, 22, 549-556.	1.1	21
97	Nocturnal Hypertension Is Associated with an Exacerbation of the Endothelial Damage in Preeclampsia. American Journal of Nephrology, 2008, 28, 424-430.	1.4	21
98	Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology, 2008, 47, 1144-1150.	0.9	99
99	Effect of Oxidative Stress on the Status of Adhesion Molecules, Nuclear Receptors and Cholesterol Flux in Endothelial Cells: Priming of Monocytes. Clinical Medicine Cardiology, 2008, 2, CMC.S708.	0.1	0
100	Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors. Current Cardiology Reviews, 2008, 4, 116-122.	0.6	87
101	Natural Antibodies against Phosphorylcholine in Cardiovascular Disease. Annals of the New York Academy of Sciences, 2009, 1173, 292-300.	1.8	50
102	Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1124-1136.	2.2	63
103	Low level natural antibodies against phosphorylcholine: A novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clinical Immunology, 2010, 134, 47-54.	1.4	74
104	Tgif1 represses apolipoprotein gene expression in liver. Journal of Cellular Biochemistry, 2010, 111, 380-390.	1.2	17
105	Pro- and Anti-Inflammatory Cytokine Networks in Atherosclerosis. ISRN Vascular Medicine, 2012, 2012, 1-17.	0.7	15
106	Soil microbial properties under different vegetation types on Mountain Han. Science China Life Sciences, 2013, 56, 561-570.	2.3	21
107	Inflammation and atherosclerosis: direct versus indirect mechanisms. Current Opinion in Pharmacology, 2013, 13, 154-160.	1.7	74
108	Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine. Prostaglandins and Other Lipid Mediators, 2013, 106, 72-78.	1.0	23
109	The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts. Mediators of Inflammation, 2013, 2013, 1-13.	1.4	208
110	Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus. Current Cardiology Reviews, 2013, 9, 15-19.	0.6	43
111	Role of Oxidized LDL in Atherosclerosis. , 0, , .		22

#	Article	IF	CITATIONS
112	Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases. Journal of Diabetes Research, 2016, 2016, 1-8.	1.0	37
113	Effect of quercetin and its metabolite on caveolin-1 expression induced by oxidized LDL and lysophosphatidylcholine in endothelial cells. Journal of Clinical Biochemistry and Nutrition, 2016, 58, 193-201.	0.6	28
114	Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function. Biochemical Pharmacology, 2017, 139, 15-23.	2.0	102
115	New Insights into the Role of Inflammation in the Pathogenesis of Atherosclerosis. International Journal of Molecular Sciences, 2017, 18, 2034.	1.8	277
116	A Quantitative Model of Early Atherosclerotic Plaques Parameterized Using In Vitro Experiments. Bulletin of Mathematical Biology, 2018, 80, 175-214.	0.9	13
117	Serum oxLDL–β2GPI complex reflects metabolic syndrome and inflammation in adipose tissue in obese. International Journal of Obesity, 2018, 42, 405-411.	1.6	1
118	Cinnamaldehyde exerts vasculoprotective effects in hypercholestrolemic rabbits. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 1203-1219.	1.4	16
119	A Spatially Resolved and Quantitative Model of Early Atherosclerosis. Bulletin of Mathematical Biology, 2019, 81, 4022-4068.	0.9	7
120	Nitric Oxide (Prong-2). , 2019, , 71-138.		1
121	Biomarkers in Metabolic Syndrome. , 0, , .		3
121 122	Biomarkers in Metabolic Syndrome. , 0, , . The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10, 2828.	1.5	3 123
121 122 123	Biomarkers in Metabolic Syndrome., 0, , .         The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10, 2828.         Potential of Lipoprotein-Based Nanoparticulate Formulations for the Treatment of Eye Diseases.         Biological and Pharmaceutical Bulletin, 2020, 43, 596-607.	1.5 0.6	3 123 4
121 122 123 124	Biomarkers in Metabolic Syndrome., 0, , .         The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10, 2828.         Potential of Lipoprotein-Based Nanoparticulate Formulations for the Treatment of Eye Diseases.         Biological and Pharmaceutical Bulletin, 2020, 43, 596-607.         Macrophage-derived myeloid differentiation protein 2 plays an essential role in ox-LDL-induced inflammation and atherosclerosis. EBioMedicine, 2020, 53, 102706.	1.5 0.6 2.7	3 123 4 41
121 122 123 124 125	Biomarkers in Metabolic Syndrome. , 0, , .         The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10, 2828.         Potential of Lipoprotein-Based Nanoparticulate Formulations for the Treatment of Eye Diseases.         Biological and Pharmaceutical Bulletin, 2020, 43, 596-607.         Macrophage-derived myeloid differentiation protein 2 plays an essential role in ox-LDL-induced inflammation and atherosclerosis. EBioMedicine, 2020, 53, 102706.         Mitochondrial Oxidative Stress and "Mito-Inflammation†Actors in the Diseases. Biomedicines, 2021, 9, 216.	1.5 0.6 2.7 1.4	3 123 4 41 63
121 122 123 124 125 126	Biomarkers in Metabolic Syndrome., 0, , .         The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10, 2828.         Potential of Lipoprotein-Based Nanoparticulate Formulations for the Treatment of Eye Diseases.         Biological and Pharmaceutical Bulletin, 2020, 43, 596-607.         Macrophage-derived myeloid differentiation protein 2 plays an essential role in ox-LDL-induced inflammation and atherosclerosis. EBioMedicine, 2020, 53, 102706.         Mitochondrial Oxidative Stress and "Mito-Inflammation†Actors in the Diseases. Biomedicines, 2021, 9, 216.         Therapeutic Potential of Quercetin to Alleviate Endothelial Dysfunction in Age-Related Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 2021, 8, 658400.	1.5 0.6 2.7 1.4 1.1	3 123 4 41 63 51
121 122 123 124 125 126	Biomarkers in Metabolic Syndrome., 0, , .         The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10, 2828.         Potential of Lipoprotein-Based Nanoparticulate Formulations for the Treatment of Eye Diseases. Biological and Pharmaceutical Bulletin, 2020, 43, 596-607.         Macrophage-derived myeloid differentiation protein 2 plays an essential role in ox-LDL-induced inflammation and atherosclerosis. EBioMedicine, 2020, 53, 102706.         Mitochondrial Oxidative Stress and "Mito-Inflammationâ€t Actors in the Diseases. Biomedicines, 2021, 9, 216.         Therapeutic Potential of Quercetin to Alleviate Endothelial Dysfunction in Age-Related Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 2021, 8, 658400.         Cardiovascular disease and stroke risk assessment in patients with chronic kidney disease using integration of estimated glomerular filtration rate, ultrasonic image phenotypes, and artificial intelligence: a narrative review. International Angiology, 2021, 40, 150-164.	1.5 0.6 2.7 1.4 1.1	3 123 4 41 63 51 15
121 122 123 124 125 126 127 128	Biomarkers in Metabolic Syndrome., 0, , .         The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10, 2828.         Potential of Lipoprotein-Based Nanoparticulate Formulations for the Treatment of Eye Diseases.         Biological and Pharmaceutical Bulletin, 2020, 43, 596-607.         Macrophage-derived myeloid differentiation protein 2 plays an essential role in ox-LDL-induced inflammation and atherosclerosis. EBioMedicine, 2020, 53, 102706.         Mitochondrial Oxidative Stress and "Mito-Inflammationâ€+ Actors in the Diseases. Biomedicines, 2021, 9, 216.         Therapeutic Potential of Quercetin to Alleviate Endothelial Dysfunction in Age-Related Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 2021, 8, 658400.         Cardiovascular disease and stroke risk assessment in patients with chronic kidney disease using integration of estimated glomerular filtration rate, ultrasonic image phenotypes, and artificial intelligence: a narrative review. International Angiology, 2021, 40, 150-164.         Mechanisms of LDL Oxidation. Developments in Cardiovascular Medicine, 2000, , 75-98.	1.5 0.6 2.7 1.4 1.1 0.4 0.1	3 123 4 41 63 51 15 2

#	Article	IF	CITATIONS
130	Chronic Allograft Nephropathy: The Inevitable Outcome of Renal Transplantation?. Current Topics in Pathology Ergebnisse Der Pathologie, 1999, 92, 37-60.	0.2	6
131	Antioxidant Protection of Low-Density Lipoprotein and Its Role in the Prevention of Atherosclerotic Vascular Disease. , 1994, , 303-351.		33
132	Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity. Journal of Lipid Research, 1996, 37, 1012-1021.	2.0	50
133	Inhibition of Low-Density Lipoprotein Oxidation by Oral Herbal Mixtures Maharishi Amrit Kalash-4 and Maharishi Amrit Kalash-5 in Hyperlipidemic Patients. American Journal of the Medical Sciences, 1997, 314, 303-310.	0.4	11
134	Vitamin E Inhibits Low-Density Lipoprotein–Induced Adhesion of Monocytes to Human Aortic Endothelial Cells In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 429-436.	1.1	115
135	Platelet-Activating Factor and Oxidized LDL Induce Immune Activation by a Common Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 963-968.	1.1	91
136	Low-Density Lipoprotein Induces Vascular Adhesion Molecule Expression on Human Endothelial Cells. Hypertension, 1995, 25, 511-516.	1.3	44
137	Ischemia-Induced Transplant Arteriosclerosis in the Rat. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 145-155.	1.1	53
138	Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits Journal of Clinical Investigation, 1993, 91, 1282-1288.	3.9	109
139	Vitamin C and Cardiovascular Diseases. , 2001, , .		1
139 140	Vitamin C and Cardiovascular Diseases. , 2001, , . The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation. Current Pharmaceutical Design, 2017, 23, 2754-2766.	0.9	1 35
139 140 141	<ul> <li>Vitamin C and Cardiovascular Diseases., 2001, , .</li> <li>The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation. Current Pharmaceutical Design, 2017, 23, 2754-2766.</li> <li>An Angiotensin-Converting Enzyme Inhibitor Suppresses the Expression of Vascular Cell Adhesion Molecule-1 and Production of Cytokines Induced in Activated Endothelial Cells. Journal of Clinical Biochemistry and Nutrition, 2002, 32, 43-54.</li> </ul>	0.9	1 35 2
139 140 141 142	Vitamin C and Cardiovascular Diseases., 2001, , .         The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation.         Current Pharmaceutical Design, 2017, 23, 2754-2766.         An Angiotensin-Converting Enzyme Inhibitor Suppresses the Expression of Vascular Cell Adhesion Molecule-1 and Production of Cytokines Induced in Activated Endothelial Cells. Journal of Clinical Biochemistry and Nutrition, 2002, 32, 43-54.         A Rationale for Antioxidant Use in Cardiovascular Disease. Developments in Cardiovascular Medicine, 2000, , 145-159.	0.9 0.6 0.1	1 35 2 0
139 140 141 142 143	Vitamin C and Cardiovascular Diseases., 2001, , .         The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation.         Current Pharmaceutical Design, 2017, 23, 2754-2766.         An Angiotensin-Converting Enzyme Inhibitor Suppresses the Expression of Vascular Cell Adhesion Molecule-1 and Production of Cytokines Induced in Activated Endothelial Cells. Journal of Clinical Biochemistry and Nutrition, 2002, 32, 43-54.         A Rationale for Antioxidant Use in Cardiovascular Disease. Developments in Cardiovascular Medicine, 2000, , 145-159.         Antioxidants and Restenosis: Animal and Clinical Studies. Developments in Cardiovascular Medicine, 2000, , 349-359.	0.9 0.6 0.1 0.1	1 35 2 0
<ul> <li>139</li> <li>140</li> <li>141</li> <li>142</li> <li>143</li> <li>144</li> </ul>	Vitamin C and Cardiovascular Diseases., 2001, , .         The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation. Current Pharmaceutical Design, 2017, 23, 2754-2766.         An Angiotensin-Converting Enzyme Inhibitor Suppresses the Expression of Vascular Cell Adhesion Molecule-1 and Production of Cytokines Induced in Activated Endothelial Cells. Journal of Clinical Biochemistry and Nutrition, 2002, 32, 43-54.         A Rationale for Antioxidant Use in Cardiovascular Disease. Developments in Cardiovascular Medicine, 2000, , 145-159.         Antioxidants and Restenosis: Animal and Clinical Studies. Developments in Cardiovascular Medicine, 2000, , 349-359.         Autoantibodies to Endothelial Cells and Oxidized LDL in Human Atherosclerosis and Hypertension. , 2001, , 161-171.	0.9 0.6 0.1 0.1	1 35 2 0 0
<ul> <li>139</li> <li>140</li> <li>141</li> <li>142</li> <li>143</li> <li>144</li> <li>146</li> </ul>	Vitamin C and Cardiovascular Diseases., 2001, , .         The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation.         Current Pharmaceutical Design, 2017, 23, 2754-2766.         An Angiotensin-Converting Enzyme Inhibitor Suppresses the Expression of Vascular Cell Adhesion Molecule-1 and Production of Cytokines Induced in Activated Endothelial Cells. Journal of Clinical Biochemistry and Nutrition, 2002, 32, 43-54.         A Rationale for Antioxidant Use in Cardiovascular Disease. Developments in Cardiovascular Medicine, 2000, , 145-159.         Antioxidants and Restenosis: Animal and Clinical Studies. Developments in Cardiovascular Medicine, 2000, , 349-359.         Autoantibodies to Endothelial Cells and Oxidized LDL in Human Atherosclerosis and Hypertension. , 2001, , 161-171.         Clinical Aspects of Gout and Associated Disease States. , 2013, , 91-185.	0.9 0.6 0.1 0.1	1 35 2 0 0 0
<ul> <li>139</li> <li>140</li> <li>141</li> <li>142</li> <li>143</li> <li>144</li> <li>144</li> <li>146</li> <li>147</li> </ul>	Vitamin C and Cardiovascular Diseases., 2001,         The Potential Protective Effects of Phenolic Compounds against Low-density Lipoprotein Oxidation.         Current Pharmaceutical Design, 2017, 23, 2754-2766.         An Angiotensin-Converting Enzyme Inhibitor Suppresses the Expression of Vascular Cell Adhesion Molecule-1 and Production of Cytokines Induced in Activated Endothelial Cells. Journal of Clinical Biochemistry and Nutrition, 2002, 32, 43-54.         A Rationale for Antioxidant Use in Cardiovascular Disease. Developments in Cardiovascular Medicine, 2000, , 145-159.         Antioxidants and Restenosis: Animal and Clinical Studies. Developments in Cardiovascular Medicine, 2000, , 349-359.         Autoantibodies to Endothelial Cells and Oxidized LDL in Human Atherosclerosis and Hypertension. , 2001, , 161-171.         Clinical Aspects of Cout and Associated Disease States. , 2013, , 91-185.         Atherosclerosis and platelet derived growth factors. Developments in Cardiovascular Medicine, 1993, , 169-187.	0.9 0.6 0.1 0.1	1 35 2 0 0 0 0 3 1

IF ARTICLE CITATIONS Modulators of Chronic Rejection., 1993, , 135-143. 149 0 The Distribution of Adhesion Molecules in Normal and Atherosclerotic Aarteries and Aortas., 1995, 159-172. The Endothelium and the Pathogenesis of Chronic Vascular Diseases: The Protective Role of Calcium 151 0 Antagonists., 1995, , 97-107. Effects of Low Density Lipoproteins on Endothelial Cell Signaling and Adhesion Molecule Expression. , 1996, , 173-184. Transplantation atherosclerosis: Definition and pathogenesis., 1997, , 39-48. 153 0 Risk Factors for Cardiovascular Disease and the Endothelium. Medical Science Symposia Series, 1998, , 313-323. Vitamin C and Cardiovascular Disease: Mechanisms of Action., 1998, , 59-71. 155 0 Emerging roles of ferroptosis in infectious diseases. FEBS Journal, 2022, 289, 7869-7890. 2.2 Cardiovascular/Stroke Risk Stratification in Parkinson's Disease Patients Using Atherosclerosis 157 1.3 21 Pathway and Artificial Intelligence Paradigm: A Systematic Review. Metabolites, 2022, 12, 312. Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson's Disease 1.3 Affected by COVID-19: A Narrative Review. Diagnostics, 2022, 12, 1543. Knockdown of hsa\_circ\_0005699 attenuates inflammation and apoptosis induced by ox-LDL in human umbilical vein endothelial cells through regulation of the miR-450b-5p/NFKB1 axis. Molecular Medicine 161 1.1 6 Reports, 2022, 26, . Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: a narrative review. Rheumatology 1.5 International, 0, , .

164 Growth factors reviews. , 2024, , 19-112.

**CITATION REPORT**